Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult ...

AbbVie (NYSE: ABBV) today announced that nine provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...

AbbVie (NYSE: ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...

Narus Financial Partners LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 8.4% in the 3rd quarter, ...

AbbVie (NYSE:ABBV – Free Report) had its target price upped by BMO Capital Markets from $214.00 to $220.00 in a research note ...

Genmab GMAB over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes ...

This growth is anticipated to be driven primarily by Darzalex and another product, Epkinly. The company, however, is preparing to confront a significant revenue gap post-patent expiration. Analyst ...

Cologuard Plus is expected to be available next year. The US Food and Drug Administration (FDA) has approved the Cologuard Plus test for colorectal cancer screening in adults age 45 years and ...

In this article, we will discuss the 10 Stocks with Biggest Upside Potential According to Hedge Funds. The US equities saw a strong move after the September jobs report exceeded the economists ...

AbbVie Inc. and its subsidiaries were hit with a lawsuit alleging they failed to warn consumers that the fat removal system CoolSculpting could cause permanent side effects. The system, which claims ...